Search Results for Marathon

Showing 1 – 3

The Next Emflaza: Acer Therapeutics Looks to Take a Page Out of Marathon's Book By Zachary Brennan - Published 18 January 2018

Last year, Marathon Pharmaceuticals took an inexpensive steroid available for sale in the EU and Canada and brought it through the US Food and Drug Administration's (FDA) approval process before trumpeting an $89,000 annual price.

Categories: News, US, FDA, Drugs, Regulatory intelligence, Regulatory strategy

Tags: Emflaza, Marathon, Acer, Shkreli

Senators Ask GAO to Probe Orphan Drug Act as Questions Pile up Over Marathon’s Pricey Steroid By Zachary Brennan - Published 06 March 2017

As US Duchenne Muscular Dystrophy (DMD) patients may be hit with a 50 to 70 times more expensive price for a steroid they have been importing from the EU and Canada for about $1,000 per year, eight Democratic senators sent a letter on Friday to Marathon Pharmaceuticals questioning the orphan drug Emflaza’s (deflazacort) $89,000 list price, while three Republican senators on Friday also asked the US Government Accountability Office (GAO) to look into orphan drugs in general.

Categories: News, US, Drugs, Ethics, Government affairs

Tags: Emflaza, deflazacort, Marathon Pharmaceuticals, Warren, Booker

Sanders, Cummings Slam Marathon’s $89,000 Price Tag for Old Steroid By Zachary Brennan - Published 13 February 2017

Sen. Bernie Sanders (D-VT) and Rep. Elijah Cummings (D-MD) on Monday wrote to Illinois-based Marathon Pharmaceuticals CEO Jeffrey Aronin, calling the company’s plan to charge $89,000 annually for its recently approved treatment “outrageous.”

Categories: News, US, FDA, Biologics and biotechnology, Crisis management, Drugs, Government affairs

Tags: Marathon, Emflaza, Deflazacort, steroid, DMD